Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Pharma (IGC) over the last 17 years, with Q1 2025 value amounting to $11000.0.

  • Pharma's Gains from Investment Securities changed N/A to $11000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was -$1000.0, marking a year-over-year increase of 9846.15%. This contributed to the annual value of $25000.0 for FY2025, which is 11623.38% up from last year.
  • Per Pharma's latest filing, its Gains from Investment Securities stood at $11000.0 for Q1 2025.
  • In the past 5 years, Pharma's Gains from Investment Securities ranged from a high of $66000.0 in Q1 2023 and a low of -$2.0 million during Q1 2021
  • For the 5-year period, Pharma's Gains from Investment Securities averaged around -$270625.0, with its median value being -$7500.0 (2023).
  • As far as peak fluctuations go, Pharma's Gains from Investment Securities crashed by 1121111.11% in 2021, and later surged by 15384.62% in 2024.
  • Over the past 5 years, Pharma's Gains from Investment Securities (Quarter) stood at $27000.0 in 2021, then crashed by 488.89% to -$105000.0 in 2022, then surged by 75.24% to -$26000.0 in 2023, then skyrocketed by 153.85% to $14000.0 in 2024, then fell by 21.43% to $11000.0 in 2025.
  • Its Gains from Investment Securities stands at $11000.0 for Q1 2025, versus $14000.0 for Q4 2024 and -$26000.0 for Q4 2023.